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RESUMO
O controlo da dor é fundamental no tratamento do cancro. Apesar da vasta utilização e do reconhecimento das normas de orientação 
clínica para o controlo da dor oncológica, o sofrimento evitável é ainda prevalente em doentes com cancro. Existe um hiato entre o co-
nhecimento e a prática clínica no que concerne a uma adequada gestão da dor pelos doentes, cuidadores, profissionais e instituições 
de saúde. Os opióides representam o pilar do tratamento farmacológico da dor moderada a insuportável. A prescrição de analgésicos 
opióides - por um médico credenciado, para o controlo absoluto da dor, - é uma prática legítima.  Neste artigo debruçamo-nos sobre 
as hesitações dos médicos e os receios dos doentes perante a morfina e similares. Examinamos os preconceitos que promovem o 
fracasso do uso terapêutico dos opióides e, consequentemente condicionam o controlo inadequado da dor.
Palavras-chave: Analgésicos Opióides; Cuidados Paliativos; Dor/tratamento; Medição da Dor; Neoplasias/complicações.
ABSTRACT
Pain relief is vital to the treatment of cancer. Despite the widespread use and recognition of clinical recommendations for the 
management of cancer-related pain, avoidable suffering is still prevalent in patients with malignant disease. A gap exists between 
what is known about pain medical management and actual practices of patients, caregivers, healthcare professionals and institutions. 
Opioids are the pillar of the medical management of moderate to severe pain. The prescription of opioid analgesics – by a registered 
medical practitioner for absolute pain control – is a legitimate practice. In this article we look at patients’ fears and physicians’ general 
hesitations towards morphine and alike. We examine misconceptions that yield fallacies on the therapeutically use of opioids and, 
therefore, sustain inadequate pain management.
Keywords: Analgesics, Opioid; Neoplasms/complications; Pain/drug therapy; Pain Measurement; Palliative Care.
INTRODUCTION
 Pain is one of the most afflicting symptoms reported by 
cancer patients, mainly those with metastatic disease.1 Pain 
prevalence in advanced cancer is about 70%, but rates 
vary per both cancer type and disease stage.2 Over 80% 
of metastatic cancer patients suffer pain caused mostly 
by direct tumor infiltration.1 Surgery, radiotherapy and/
or chemotherapy contribute to, approximately, 20% of the 
cases of cancer-related pain (CRP).3
PREVALENCE OF CANCER-RELATED PAIN
 Accurate prevalence estimates of pain in cancer patients 
are not available despite the abundant literature on this 
topic. Van den Beuken-van Everdingen et al investigated 
the prevalence of CRP throughout a systematic review of 
the literature.4 Fifty-two studies were used in the meta-
analysis. Pooled prevalence rates of pain were calculated 
for 4 subgroups: patients after curative treatment (33%); 
patients under anticancer treatment (59%); patients with 
advanced, metastatic, terminal disease (64%) and; patients 
at all disease stages (53%). More than one-third of the 
patients had moderate to severe cancer pain (MSCP). 
Pooled prevalence was above 50% in all cancer types 
with the highest prevalence in head/neck cancer patients 
(70%).4
 The European Pain in Cancer (EPIC) was a two-phase 
telephone survey, held in 11 European countries and Israel, 
with 5 084 adults with all stages of cancer.5 From these, 56% 
mentioned MSCP, at least, monthly. In a second phase, 573 
patients were randomly selected: 90% had MSCP, 44% had 
severe CRP. Global prevalence was 73%.5
UNDERTREATMENT OF CANCER-RELATED PAIN
 Pain considerably weakens quality of life and represents, 
clinically, an indicator of tumor progression. CRP may be 
acute or chronic and should be addressed accordingly.3 
 The World Health Organization (WHO) has published 
some guidelines on CRP management and has been 
underlining the existence of several treatments, which are 
effective in 70 - 90% of the circumstances.6,7 
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inadequate management of pain has been found in 
cancer patients, mainly: seniors,8 metastatic outpatients,9 
children10 and minority patients.11 This is due to hurdles 
associated with such factors as: health care providers 
(HCP), patients, families, institutions, governments and 
society.12 The most frequent cause of undertreatment is 
misconception about opioids.13 
 Potential causes of undertreatment of CRP are: fear 
of prescribing opioids, lack of knowledge concerning 
adequate pain treatment, and patient-related barriers on 
using opioids.14,15 Lack of compliance may cause pain 
undertreatment, especially if opioids are only prescribed ‘as 
required’.16 
 Treatment failure may also be caused by the incapacity 
to recognize specific cancer pain syndromes.14 The Task 
Force on Cancer Pain of the International Association for the 
Study of Pain (IASP) identified 22 prevalent pain syndromes 
and observed that 40% of cases had a neuropathic 
component explaining their pain.17 Management of that 
kind of pain involves adjuvant therapies besides classical 
analgesics.18 
 Large proportions of up to 40% cancer patients remain 
intentionally undertreated.19
 The inadequacy of CRP treatment was also demonstrated 
by the IASP.17 It showed that among 1095 patients treated 
by pain specialists, 20% confessed average pain intensity 
of ≥ 7 (range 0 - 10) and 67% reported worse pain of ≥ 7.  
 Cleeland et al observed that 42% of 1308 metastatic 
cancer outpatients were not given adequate analgesics.9
 In France, Vainio found that only 25% of general 
practitioners (GP) and 44% of specialists suggested 
strong opioid to control CRP.20 For instance, for metastatic 
bone pain a third of GP recommended a combination of 
paracetamol and codeine. Overall, only 10% of GP and 21% 
of specialists prescribed adequate treatment. Consequently, 
92% of the physicians had trouble in managing CRP, 
inefficacy of treatment being the most important problem.20
 Sorge et al, in the region of Hannover (Germany), 
documented that approximately 23% of GP and 34% of 
internal medicine specialists prescribed opioids. In two-
thirds of cases CRP was the reason for the prescribing. 
Taking into account the estimated number of cancer 
patients, less than 20% of those in need of strong opioids 
were supplied sufficiently.21 
 A Norwegian survey observed that, even in cancer 
patients reporting an average pain score of ≥ 7, only 13% 
was prescribed morphine.22 
 In the Treviso district (Italy) a retrospective survey of 
the opioids prescriptions issued for 2125 cancer outpatients 
was carried out over the 1993 - 2000 period.23 They verified 
whether patients received adequate opioid prescription 
accordingly to the Defined Daily Doses (DDD) of opioids 
suggested by the WHO for a standard population. From 
the comparison between the number of ‘expected opioid 
DDD’ (days for which patients should have been prescribed 
opioids at the WHO recommended DDD) and the number 
of ‘prescribed opioid DDD’ (days for which patients had 
been offered adequate opioid treatment) for individual 
patients, it was estimated that only 38% of prescriptions 
were adequate. A mean of 55.8 DDD of opioids per patient 
was not prescribed. The opioid prescription inadequacy 
increased over time since the first recommendation until the 
patient’s death.23
 Chinellato et al, in Italy, revealed that only 21% of dying 
cancer patients (n = 39 597) were prescribed opioids at the 
time of death. Prescribed ‘morphine equivalent daily dose’ 
was low: morphine (45 mg) and buprenorphine (53.25 mg). 
Higher doses existed as per injected morphine (90 mg) and 
per transdermal fentanyl (180 mg).24
LACK OF OPIOIDS, FEAR OF ADDICTION AND STRICT 
REGULATION 
 Adequate treatment of CRP depends on the availability 
of safe and effective drugs, capable of relieving chronic 
MSCP, such as morphine and other opioids.25 A successful 
implementation has been curtailed by the following: lack 
of opioid analgesics, exaggerated fear of addiction and 
excessively strict regulation of narcotic drugs.26
 Across the world, pain patients are facing poor drug 
availability. About 5.5 billions are living in countries 
with insufficient or no access to medications for MSCP, 
according to the WHO’s Access to Controlled Medications 
Programme.27
 In many countries, the law establishes quantity 
and duration limits regarding the opioids’ prescriptions. 
Physicians who prescribe them are imposed to fulfill certain 
requirements. Moreover, HCP and legislators may not 
realize that there is a need for pain relief; they are likely to be 
mainly concerned about narcotic addiction and diversion.25 
 Morphine-phobia can be defined as an array of false 
beliefs based on the negative effects of morphine in the 
management of pain. It represents an inappropriate attitude 
of professionals due to lack of knowledge, philosophical 
opposition to its prescription and morphine administration 
in pain patients’ related myths.28 Opioid-phobia seems to 
be widespread and caused by ignorance, prejudices, false 
beliefs, economic marketing strategies and limitations in the 
availability of opioids.29-32 
 In 1986, the WHO recommended that HCP should use a 
three-step analgesic ladder to treat CRP.6 The International 
Narcotics Control Board transnational survey, performed 
ten years later, showed that injectable forms of morphine 
were more available than the oral ones recommended by 
the WHO.33 In this inquiry, half of the governments reported 
that morphine was not available in all hospitals where CRP 
is dealt with. In addition, only 60% of governments had 
endorsed WHO’s analgesic ladder.33
 The WHO considers a country’s morphine consumption 
(MOC) to be an important indicator of progress in cancer 
pain relief34 because morphine is the most common opioid 
analgesic for MSCP.25 MOC for medical purposes was 
low and stable worldwide for many years until, in 1984, 
the WHO’s cancer pain relief program began. From 1984 
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extremely low, and many governments around the world still 
have to address this chief health priority.25 
 The classic tight regulation of opioids prescription, the 
ordinance of their use for the treatment of ‘narcotic addiction’ 
and the misunderstanding of addiction itself have contributed, 
altogether, to an even greater confusion regarding licitness 
of prescription under certain circumstances.36,37
 Neither physical dependence nor tolerance are sufficient 
to define addiction.7,38,39 In fact, in 1969, the WHO substituted 
the term ‘addiction’ for ‘drug dependence’ which, like 
addiction, is characterized, primarily, by a compulsive use 
of a drug despite its harmful effects.40 Confusion between 
physical dependence or tolerance and addiction raises the 
possibility that an opioid, prescribed to a patient with chronic 
MSCP, could be viewed as questionable medical practice, 
if not illegal.39 Furthermore, a recent review of literature 
reports that addiction to opioids is present only in 0 - 7.7% 
of cancer patients, depending on the subpopulation studied 
and the evaluation criteria used.41 
 On the 12th November 2003, at the 860th meeting of 
the Ministers’ Deputies, the Committee of Ministers of the 
Council of Europe, as part of its Recommendation 24 to 
Member States, declared: “legislation should make opioids 
and other medicines accessible in a range of formulations 
and dosages for medical use. The fear of abuse should 
not hinder access to necessary and effective medication. 
Countries may wish to consider whether this will require a 
new legislation whether an amendment should be applied 
to the existing legislation”.42
 Several criteria are used to evaluate positive or negative 
medical board policies to pain management. The former 
identifies policy language that has the potential to enhance 
pain management and the latter, on the contrary, may impair 
pain management. 
 Some positive criteria favouring adequate pain relief 
are43: 
a) Pain management is recognized as part of general 
medical practice;
b) Controlled substances are recognized as necessary 
for the public health;
c) Medical use of opioids is recognized as legitimate 
professional practice;
d) Practitioners’ concerns about regulatory scrutiny are 
addressed;
e) Physical dependence or analgesic tolerance are not 
mistaken for ‘addiction’. 
 In contrast, negative criteria that impede pain control 
are43: 
a) Opioids are considered a last resort treatment;
b) The belief that opioids hasten death is perpetuated;
c) Medical decisions are restricted: i) based on patient 
characteristics, ii) mandated consultations, iii) 
regarding quantity prescribed or dispensed;
d) Length of prescription validity is restricted;
e) Practitioners are under additional prescription 
requirements.
PHYSICIANS’ CONCERNS ON PAIN AND OPIOIDS
 Currently the association ‘opioids, pain, and fear’ 
continues to haunt some doctors who assist, on a daily basis, 
cancer patients and their multidimensional problems.44 
Things should be different nowadays. Twenty years ago, 
18% of oncologists rated opioids analgesics excessive 
regulation as one of the top barriers for inadequate CRP 
management.45 Multiple copy prescription schemes and 
specific formularies for opioids did not ease physicians’ 
hesitations.46 
 Amongst barriers that contribute to inadequate pain 
treatment, physicians’ various fears are not negligenciable. 
There is fear both of prescribing opioids and of being 
investigated for prescribing those36. Some studies approach 
that matter.
 In the USA, 243 physicians engaged in cancer care 
misunderstood concepts of morphine tolerance (51%) 
and side effects (39%). Some were unaware of the use 
of adjuvant analgesics (29%), efficacy of oral morphine 
(27%) and non-existent risk of addiction (20%). About 
20% believed that pain was inevitable and could not be 
diminished by treatment.47
 Randomly selected licensed American physicians (n = 
600) were surveyed.48 The majority considered addiction 
to be a combination of physiological and behavioral 
characteristics, rather than defining it solely as a behavioral 
syndrome. Most physicians felt it lawful and acceptable 
medical practice to prescribe opioids for CRP, but only half 
held this view in chronic non-cancer pain. Fewer physicians 
considered such prescribing if the patient had a history 
of substance abuse. About two-thirds of physicians were 
not concerned about being investigated for their opioid 
prescribing practices, but some admitted that fear and 
tended to lower the dose prescribed, limit the number of 
refills, or prescribe WHO’s step 1 ou 2 rather than step 3 
analgesics.48
 In France, 76% of 600 GP and 50% of 300 oncologists 
were reluctant to prescribe morphine.49 Both groups 
mentioned fear of side effects as the main reason, as well 
as concerns about the risk of tolerance, morphine’s poor 
public image and the constraints of prescription forms. 
Doctors with more prejudice about opioids were women and 
older oncologists.49 Varela & Aubry revealed, also in France, 
that more than 60% of doctors thought that morphine had a 
ceiling dose.50
 As per 1 082 dying patients, French GP and oncologists 
prescribe opioids in 85.4% of them. Prescription was 
less frequent in the cases of female patients and male 
physicians, and more frequent if physicians were trained in 
palliative care.51 
 Ben Diane et al conducted a phone survey amongst a 
sample of 917 French GP, neurologists and oncologists. 
Beliefs towards morphine, uneasiness with dying patients, 
age and female gender were independently associated with 
reluctance to prescribe morphine.52
 In northern Italy, 104 GP responded to a questionnaire 
about opioids.23 Most of them feared side effects, such 
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as respiratory depression (50%), constipation (42%), 
and addiction (9%). Many considered opioids capable of 
reducing length of life (22%) and inappropriate to pediatric 
patients (51%). Some GP experienced pressure by patients’ 
relatives against opioids (44%) and 58% considered 
legislation ineffective for improving their prescribing 
pattern.23
 In Canada, Gallagher et al surveyed 4 618 physicians 
on CRP and verified that oncologists had the highest 
knowledge and surgeons the lowest. Those who practiced in 
smaller communities had higher knowledge. The questions 
most frequently answered incorrectly were on equianalgesic 
(68%) and adequate breakthrough dosing (45%).53
 In Korea, a nationwide questionnaire survey showed 
that although physicians had better knowledge of pain 
management than nurses, both groups lacked knowledge 
on opioids. Physicians identified perceived patients’ 
reluctance to take opioids as a barrier to pain control.54 
PATIENTS’ ISSUES AND CANCER-RELATED PAIN 
 This is a very sensitive matter. On one hand, it is known, 
patients and their carers or family can act as barriers to pain 
management and contribute to CRP undertreatment. On 
the other hand, there are patients complaining about the 
little assistance their HCP offered in CRP management.  
 In the EPIC survey,5 patients affirmed that CRP: 
prevented them from concentrating or thinking (51%), 
undermined daily life activities’ performance (69%), made 
them feel as an increasing burden to others (43%) and 
made them unable to self-caring or impede them to help 
others because they were in too much pain (30%). Of those 
still working, 52% said that pain affected their professional 
performance. CRP was described as distressing by 67% of 
patients, as an intolerable aspect of their cancer by 36% 
and 32% stated that they felt so bad they wanted to die.5
 Patient beliefs about their HCP were not always 
fantastic as per EPIC’s results.5 Patients affirmed that their 
HCP did not: take into consideration quality of life (50%); 
have enough time to discuss pain (33%); always ask about 
pain (27%); know how to control pain (26%); understand 
that pain was a problem (13%). Their HCP preferred to treat 
cancer rather than pain (38%).5
 Most of the articles in the literature depicted patient-
related barriers toward the use of opioids.14,15,55-58
 In Turkey, 170 patients with CRP were studied, using 
a questionnaire.57 It was found that patients had barriers, 
mostly in relation to addiction, and to a small extent, physical 
side effects. It was ascertained that patients having beliefs 
that acted as barriers to optimal pain management were: 
male; unmarried; suffering from another chronic disease; 
self-assessing their average pain intensity as more than 5 in 
the last 24 hours; using an inadequate analgesic regimen.57
 Weiss et al – aware that the number of patients 
experiencing pain remained too high and that putatively 
most were willing to tolerate pain, – interviewed 988 dying 
patients from 6 randomly selected USA sites.15 Patients 
were treated by a GP, a pain specialist, or both. Findings 
showed that 50% of individuals reported MSCP; 52% had 
been assisted by a GP and 20% consulted a specialist. Of 
those who had been treated by their GP, 29% wanted more 
therapy, 62% wanted a strategy to remain the same, and 
9% wanted to reduce or stop their pain regimen. Additional 
therapy was not accepted owing to: fear of addiction, dislike 
of mental or physical side effects, and not wanting to take 
more pills or injections. There were no associations between 
disease and intensity of pain or between disease and the 
desire for more treatment. Black patients were more likely 
to seek additional pain therapy, see a specialist, and refuse 
additional medication because of fear of addiction.15
 Edrington et al studied the barriers to CRP management 
in a community sample of 50 Chinese American patients.58 
Stronger individual barriers found were: tolerance to pain 
medicine; time intervals used for dosage of pain analgesics; 
disease progression; and addiction. Significant correlations 
were found between the tolerance subscale and least 
pain and the religious fatalism subscale and average 
pain. These two subscales were positively correlated with 
anxiety and depression levels. The tolerance subscale was 
associated with pain interference. Patients’ education level, 
acculturation score, level of depression, and adequacy of 
pain treatment explained approximately 21% of the variance 
in the barriers.58
 In Korea, nurses pinpointed perceived patients’ 
tendency to under-report of pain as an obstacle to adequate 
pain control.54
 A qualitative in-depth interview study was conducted 
with 18 cancer patients (aged 42 - 88 years). Participants 
rejected morphine as a medical intervention to control pain 
and promote quality of life because they saw it only as a 
comfort measure for the dying. However, opioids were 
more acceptable if HCP had confidence in opioids and side 
effects were well managed.59
 Contrarily to the results above described, in an 
Australian study some patients mentioned a wish for greater 
involvement in pain control decisions, perceiving morphine 
as a facilitator rather than a barrier to good cancer care. 
In Melbourne, semi-structured interviews were held with 15 
cancer patients (aged 24 - 81) presenting to a metropolitan 
clinic. All of them were highly supportive of morphine use in 
CRP. For them morphine is useful to treat pain, to enable 
peace and as a treatment for cancer.60
 
CONCLUSIONS
 Results from retrospective and prospective surveys 
consistently show that pain is still prevalent in cancer 
patients. Treatment of CRP is still suboptimal.5,61,62
 Medical science has learned a great deal about pain 
management in the last 25 years, even though not all of this 
knowledge has been incorporated into practice. There is a 
breach between knowledge and practice as far as adequate 
pain management is concerned.63 Irrational myths exist and 
affect both patients, caregivers, families, HCP and health-
oriented organizations.64,65
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an advanced age proves that it is of paramount importance 
to reduce the prevalence of pain at all stages of the disease 
course.4 Pain relief should be considered vital to the 
treatment of cancer.5 Incomplete or inaccurate knowledge, 
and varying attitudes about pain and the use of opioid 
medications, can and will inhibit pain management.65,66 
 Although there are many effective pharmacological and 
non-pharmacologic pain treatments available,67 opioids are 
essential for management of MSCP.39 Opioid analgesics 
have been regarded as the bastion of surgery and 
trauma related pain treatment for many years,36 national 
encouragement of their use for CRP did not occur until 
roughly ten years ago. 
 Opioids are controlled substances and are subjected 
to additional prescription requirements. Their deliberately 
conditional use, however, is not intended to affect their licit 
medical use.39 The prescription of opioid analgesics for pain 
control by a registered medical practitioner is a legitimate 
practice and is recognized as such by regulatory and 
legislative groups.68 Prescribing opioids to former or actual 
drug abusers is as legitimate, providing it targets pain rather 
than addiction management.39
 The advent of new information on pain physiology, 
opioid pharmacology, and revised conceptions of addiction 
and dependence – particularly on pseudo-addiction,69 – 
represents new knowledge that needs to be incorporated 
into medical education and practice.36,70 Strategies to 
change physician’s attitudes and beliefs regarding morphine 
in CRP management should focus on tolerance concepts, 
dosing schemes, safety, efficacy, lack of addictive risk and 
use of drug combinations.47 Of paramount importance, afar 
from individual misconceptions, is the scientific certainty: 
CRP can be relieved.
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